EUVIMEDEUVIMED entdecken
Crossref

A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression

Zhen Tang, Jing Hu, Xu-Chang Li, Wei Wang, Han-Yue Zhang, Yu-Yao Guo, Xin Shuai, Qian Chu, Conghua Xie, Dandan Lin, Bo Zhong

Developmental Cell · 2025-02 · 60 (3) · 379-395.e8

DOI: 10.1016/j.devcel.2024.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Developmental Cell, 2025-02. Verfasst von Zhen Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neutrophils, Lung Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neutrophils in the tumor microenvironment (TME) are heterogeneous populations associated with cancer prognosis and immunotherapy. However, the plasticity and function of heterogeneous neutrophils in the TME of non-small-cell lung cancer (NSCLC) remain unclear. Here, we show that neutrophils produce high levels of interleukin (IL)-8, which induce the differentiation of CD74highSiglecFlow neutrophils and suppress the generation of CD74lowSiglecFhigh neutrophils in the TME of IL-8-humanized NSCLC mice. The CD74highSiglecFlow neutrophils boost anti-tumor T cell responses via antigen cross-presentation. Deleting CD74 in IL-8-humanized neutrophils impairs T cell activation and exacerbates NSCLC progression, whereas a CD74 agonist enhances T cell activation and the efficacy of anti-programmed cell death 1 (PD-1) or osimertinib therapies. Additionally, the CD74highCD63low neutrophils in the TME and peripheral blood of advanced NSCLC patients phenocopy the CD74highSiglecFlow neutrophils in the TME of NSCLC mice and correlate well with the responsiveness to anti-PD-1 plus chemotherapies. These findings demonstrate an IL-8-CD74high neutrophil axis that promotes anti-tumor immunity in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNeutrophilsLung NeoplasmsAnimalsHumansMiceTumor MicroenvironmentDisease ProgressionInterleukin-8Histocompatibility Antigens Class IIAntigens, Differentiation, B-LymphocyteT-LymphocytesCell Line, TumorLymphocyte Activation

Stichwörter der Autor:innen

CD74IL-8immune checkpoint blockade therapyneutrophil heterogeneitynon-small-cell lung cancertumor microenvironment

Substanzen

Interleukin-8Histocompatibility Antigens Class IIinvariant chainAntigens, Differentiation, B-Lymphocyte

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China; Department of Virol…
  • Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China.
  • Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: chxie…
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China. Electronic address: lindandan@whu.edu.cn.

Förderung

  • Natural Science Foundation of Sichuan Province
  • National Natural Science Foundation of China
  • Key Technologies Research and Development Program
  • National Key Research and Development Program of China
  • Chinese Academy of Sciences
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Tang, Z., Hu, J., Li, X. C., Wang, W., Zhang, H. Y., Guo, Y. Y., Shuai, X., Chu, Q., Xie, C., Lin, D., & Zhong, B. (2025). A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression. Developmental Cell, 60(3), 379-395.e8. https://doi.org/10.1016/j.devcel.2024.10.010

Vancouver

Tang Z, Hu J, Li XC, Wang W, Zhang HY, Guo YY, et al. A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression. Developmental Cell. 2025;60(3):379-395.e8. doi:10.1016/j.devcel.2024.10.010

BibTeX
@article{Tang2025,
  author = {Tang, Zhen and Hu, Jing and Li, Xu-Chang and Wang, Wei and Zhang, Han-Yue and Guo, Yu-Yao and Shuai, Xin and Chu, Qian and Xie, Conghua and Lin, Dandan and Zhong, Bo},
  title = {A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression},
  journal = {Developmental Cell},
  year = {2025},
  volume = {60},
  number = {3},
  pages = {379--395.e8},
  doi = {10.1016/j.devcel.2024.10.010}
}
Kostenlos starten →